CNBC Business
· May 14, 2026 4:10 PM EDT
Not market news
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
